MicroSalt PLC
30 September 2026
MICROSALT PLC
(“MicroSalt” or the “Company”)
Result of Retail Offer
and
Total Voting Rights
MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt containing approximately 50% less sodium, is pleased to announce that the Retail Offer was over-subscribed and has therefore conditionally raised the full £100,000 through the issue of 714,285 new Ordinary Shares (the “Retail Offer Shares”) at 14 pence per Retail Offer Share (the “Issue Price”).
Each Retail Offer Share carries an entitlement to one warrant for every Retail Offer Share subscribed. Each warrant (the "Retail Offer Warrants") entitles the holder to subscribe for one Ordinary Share at an exercise price of 14 pence per Ordinary Share and is exercisable for a period of three years following admission. The Retail Offer Warrants will not be admitted to trading on AIM.
The issue of the Retail Offer Shares and the granting of the Retail Offer Warrants are conditional upon the passing of certain resolutions to be put to shareholders of the Company at the general meeting to be held on 2 October 2026.
The Retail Offer is conditional on the Retail Offer Shares being admitted to trading on the AIM market operated by the London Stock Exchange.
Admission and Total Voting Rights
Application has been made to London Stock Exchange plc for the admission to trading on AIM of the Retail Offer Shares (“Admission”). It is expected that Admission will become effective and dealings will commence at 8:00 a.m. on or around 5 October 2026.
Upon Admission, the Company's issued ordinary share capital will consist of 78,202,719 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 78,202,719. With effect from Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Retail Offer Shares will be issued free of all liens, charges and encumbrances and will, on Admission, rankpari passuin all respects with the New Ordinary Shares to be issued pursuant to the Subscription, the Director Subscriptions and the Company's existing Ordinary Shares.
For further information, please contact:
|
MicroSalt plc |
Via Gracechurch Group |
|
Rick Guiney, CEO Gary Urmston, Interim CFO |
|
|
|
|
|
Zeus (Nominated adviser and broker) David Foreman / Ed Beddows (Investment Banking) Nick Searle (Head of Equity Capital Markets) |
+44 (0)20 3829 5000 |
|
|
|
|
Gracechurch Group(Financial PR) |
+44 (0)20 4582 3500 |
|
Heather Armstrong, Alexis Gore, Rebecca Scott |
|
About MicroSalt
MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges.
Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.